bluebird bio (BLUE) Misses Q2 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
bluebird bio (BLUE) PT Lowered to $19 at Morgan Stanley
August 11, 2021 8:26 AM EDTMorgan Stanley analyst Matthew Harrison lowered the price target on bluebird bio (NASDAQ: BLUE) to $19.00 (from $35.00) while maintaining a Equalweight rating.
... MoreGoldman Sachs Downgrades bluebird bio (BLUE) to Neutral
August 10, 2021 6:56 AM EDTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Buy to Neutral with a price target of $23.00 (from $63.00).
The analyst comments "We downgrade BLUE from Buy to Neutral and lower our 12-month PT to $23 from $63. First, we note the newly announced clinical hold for gene therapy Lenti-D in cerebral adrenoleukodystrophy (CALD) due to a Suspected Unexpected Serious Adverse... More
bluebird bio (BLUE) PT Lowered to $18 at Stifel
August 9, 2021 1:56 PM EDTStifel analyst Benjamin J. Burnett lowered the price target on bluebird bio (NASDAQ: BLUE) to $18.00 (from $31.00) while maintaining a Hold rating.
The analyst commented, "We remain Hold rated on BLUE following two negative updates: (1) a patient treated with Lenti-D (Cerebral Adrenoleukodystrophy) developed... More
